SCHEMBL4408322

SCHEMBL4408322

OCc1ccc(-c2nc(-c3ccccc3)c(-c3ccccc3)[nH]2)cc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 4/20 0.86
MAPK13 O15264 8/20 0.65
MAPK12 P53778 8/20 0.65
MAPK11 Q15759 8/20 0.65
MAPK14 Q16539 8/20 0.65
GCGR P47871 4/20 0.65
RAF1 P04049 4/20 0.63
MAPK9 P45984 1/20 0.62
TP53 P04637 1/20 0.61
MAPT P10636 1/20 0.61
NOX1 Q9Y5S8 1/20 0.60
KMT2A Q03164 2/20 0.59
KDM4E B2RXH2 1/20 0.59
ALDH1A1 P00352 1/20 0.59
GLA P06280 1/20 0.59
GAA P10253 1/20 0.59
HPGD P15428 1/20 0.59
MEN1 O00255 1/20 0.59
PTPN1 P18031 1/20 0.58
ALOX5 P09917 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5074753 0.87 MAPK13 (0.83) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL16667652 0.85 MAPK13 (0.83) BRAFMAPK13MAPK12MAPK11MAPK14
Benzene SCHEMBL28852698 0.85 MAPK13 (0.82) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL104130 0.85 MAPK13 (0.82) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL25008485 0.84 ALOX5 (0.67) BRAFMAPK13MAPK12MAPK11MAPK14
Methane SCHEMBL3278320 0.83 MAPK13 (0.79) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL27850480 0.83 MAPK13 (0.79) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL252964 0.82 MAPK13 (0.85) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL15401173 0.82 MAPK13 (0.85) BRAFMAPK13MAPK12MAPK11MAPK14
SCHEMBL9619859 0.82 MAPK13 (0.85) BRAFMAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof REDPOINT BIO CORPORATION 2007-11-08 US claimed
EP-2015638-A2 TRIARYL SUBSTITUTED IMIDAZOLE DERIVATIVES AND TASTE-INHIBITING USES THEREOF Redpoint Bio Corporation (US) 2009-01-21 EP disclosed
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof REDPOINT BIO CORPORATION 2007-11-08 US disclosed
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof REDPOINT BIO CORPORATION 2007-11-08 US disclosed
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof REDPOINT BIO CORPORATION 2007-11-08 US disclosed
WO-2007127479-A2 TRIARYL SUBSTITUTED IMIDAZOLE DERIVATIVES AND TASTE-INHIBITING USES THEREOF REDPOINT BIO CORPORATION (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259875-A1 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof TAS1R3, TAS2R1, TAS1R1 BRAF 2365/4885MAPK13 3416/4885MAPK12 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.